The 2 Best Biotech Stocks to Buy Now

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Biotech companies are known for their potential to break out when a new drug comes to market, and today we're giving you two of the best biotech stocks to buy now.

Now that the bull market is over a decade old and valuations are near all-time highs, investors need more than an index fund to net a solid return. And buying the top biotech stocks offers the sort of upside that's so hard to find right now.

In order to find the best biotech stocks, we've turned to the Money Morning Stock VQScore.

The VQScore system is our proprietary stock-ranking algorithm that helps us separate the wheat from the chaff. The VQScore finds only the 1,500 most profitable companies trading on the major American exchanges and then ranks them based on their growth potential.

Today, we've screened the biotech industry in the VQScore system to uncover our top biotech stocks to buy right now.

Best Biotech Stocks to Buy Now, No. 2

Biogen Inc. (NASDAQ: BIIB) is a Massachusetts-based company that focuses on discovering, developing, manufacturing, and delivering therapies for neurodegenerative and neurological diseases worldwide.

The company offers four major drugs for the treatment of multiple sclerosis (MS). It also has drugs for the treatment of plaque psoriasis, spinal muscular atrophy, non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia (CLL), and pemphigus vulgaris.

5G Is Coming: The Tech Breakthrough of the Century Could Rest on This $6 Stock – Get All the Details Here

Biogen is also involved in the development of drugs to treat dementia and Alzheimer's disease, Parkinson's disease, chronic pain, and other neuromuscular disorders.

Company execs had promised to diversify its pipeline and make good this with a new acquisition. On March 4, Biogen announced that it would buy Nightstar Therapeutics Plc., a gene therapy developer, in a deal worth $877 million.

This new deal gives the company access to more later-stage assets. Specifically, Nightstar makes a gene therapy for choroideremia, an inherited and rare eye disease that can lead to blindness. It also has several gene therapies in its pipeline that are focused on treating rare eye disorders.

The company has beat earnings estimates over the past four consecutive quarters and is expected to make $28.67 per share this year. This represents 10% growth over the $26.24 EPS in 2018.

While some Wall Street analysts predict an earnings recession in 2019, this isn't a prediction for Biogen.

Growth is expected in both sales and revenue this year.

If history repeats itself and earnings bypass expectations, Biogen shares could soar past their 52-week high of $350 per share. Right now, you can pick up shares for about $319.

Currently, investors can get this stock for just 11 times expected earnings this year, which is exceptionally cheap. Plus, the company has committed to a $3.5 billion stock buyback, which is nearly 5% of its market cap.

Analysts predict shares of Biogen could soar 43% higher to $455 in the next 12 months.

But our top biotech stock to buy right now could soar even higher.

Join the conversation. Click here to jump to comments…

Best Low Price Stocks To Invest In Right Now

tags:NYNY,BAYRY,AEO,BRKR,BGG,

They say that big things come in small packages, and sometimes the same can be said about stock prices. There are plenty of stocks trading in the single digits, and while most of them -- let's face it -- are there for a reason, risk-tolerant investors can sometimes find some real gems among low-priced equities. 

Sirius XM Holdings (NASDAQ:SIRI), Glu Mobile (NASDAQ:GLUU), Fitbit (NYSE:FIT), GoPro (NASDAQ:GPRO), Zynga (NASDAQ:ZNGA), Rite Aid (NYSE:RAD), and Groupon (NASDAQ:GRPN) are some of the big names with low prices that I'm watching these days. Let's take a closer look at these seven stocks trading for $7 or less. 

Image source: Sirius XM Holdings.

1. Sirius XM Holdings -- $6.94

Not every stock trading in the single digits is a loser. Sirius XM stock has been a nearly 140-bagger since bottoming out at a nickel in 2009. The satellite radio provider has been a beast over the years. The shares are trading higher for the 10th year in a row. 

Best Low Price Stocks To Invest In Right Now: Empire Resorts Inc.(NYNY)

Advisors' Opinion:

• [By Stephan Byrd]

  Wendys (NASDAQ: WEN) and Empire Resorts (NASDAQ:NYNY) are both retail/wholesale companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

• [By Max Byerly]

  Simplicity Esports and Gaming (NASDAQ:WINR) and Empire Resorts (NASDAQ:NYNY) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.

Best Low Price Stocks To Invest In Right Now: Bayer Aktiengesellschaft (BAYRY)

Advisors' Opinion:

• [By Simon Erickson]

  That means they're actually printing the base pairs of DNA -- arranged in the proper sequence -- to synthetically create living things. One example is their recent joint venture with Bayer (NASDAQOTH:BAYRY) to engineer microbiome enzymes for soil, which is helping crops better absorb fertilizer nutrients and produce a better yield.

• [By ]

  Major competitive vendors that are developing treatments for pericarditis include:

  Pfizer Inc. (PFE) Abbvie, Inc. (ABBV) XBiotech Inc. (XBIT) Handok AstraZeneca (AZN) Bayer AG (OTCPK:BAYRY) Reckitt Benckiser Group plc. (RB) PerkinElmer, Inc. (PKI) FUJIFILM Holdings Corporation (OTCPK:FUJIY) Merck Sharp & Dohme Corp. (MRK) ALLERGAN (AGN)

  Concerning competitive advantage, management of the company is not aware of any therapies currently approved by the FDA for the treatment of recurrent pericarditis, the firm's lead indication for rilonacept.

• [By Maxx Chatsko]

  The explosion of digital agriculture tools, which marry predictive analytics with data science to make farmers more resilient to the whims of Mother Nature, has been delivered by companies across the agricultural value chain. Seed and chemical companies such as DowDuPont (NYSE:DWDP) and Bayer (NASDAQOTH:BAYRY) have plowed billions into the agtech markets. The world's largest fertilizer company, Nutrien (NYSE:NTR), has even joined the fray. There are more start-ups than can be counted.

Best Low Price Stocks To Invest In Right Now: American Eagle Outfitters, Inc.(AEO)

Advisors' Opinion:

• [By Ethan Ryder]

  Hennessy Advisors Inc. bought a new stake in American Eagle Outfitters (NYSE:AEO) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,049,261 shares of the apparel retailer’s stock, valued at approximately $26,053,000. Hennessy Advisors Inc. owned approximately 0.59% of American Eagle Outfitters at the end of the most recent quarter.

• [By Max Byerly]

  Systematic Financial Management LP grew its position in American Eagle Outfitters (NYSE:AEO) by 3.6% during the 2nd quarter, HoldingsChannel reports. The firm owned 1,229,469 shares of the apparel retailer’s stock after acquiring an additional 42,263 shares during the quarter. American Eagle Outfitters makes up approximately 0.7% of Systematic Financial Management LP’s investment portfolio, making the stock its 16th biggest position. Systematic Financial Management LP’s holdings in American Eagle Outfitters were worth $28,585,000 at the end of the most recent quarter.

• [By Chris Lange]

  American Eagle Outfitters Inc. (NYSE: AEO) also is scheduled to release its most recent quarterly results Thursday. The consensus forecast calls for $0.44 in EPS and $1.21 billion in revenue. Shares closed at $20.27. The consensus price target is $19.31, and the 52-week range is $10.23 to $20.46.

• [By Dan Caplinger]

  Wall Street had another summer celebration on Wednesday, as the S&P 500 and Nasdaq Composite once again set records. Most investors attributed the gains to a 4.2% rise in gross domestic product during the second quarter, which was slightly faster than the initial estimate on GDP had suggested last month. Yet even with a favorable attitude prevailing throughout most of the market, some stocks suffered setbacks. Movado Group (NYSE:MOV), Roku (NASDAQ:ROKU), and American Eagle Outfitters (NYSE:AEO) were among the worst performers on the day. Here's why they did so poorly.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on American Eagle Outfitters (AEO)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Demitrios Kalogeropoulos]

  Investors weren't thrilled with American Eagle's (NYSE:AEO) second-quarter earnings report, sending the stock lower immediately following the results. Yet that dip likely had more to do with the dramatic run-up that shares have had so far this year, and not with any looming issues with the company.

Best Low Price Stocks To Invest In Right Now: Bruker Corporation(BRKR)

Advisors' Opinion:

• [By Joseph Griffin]

  Bruker Co. (NASDAQ:BRKR) – Jefferies Financial Group lowered their Q1 2019 earnings per share (EPS) estimates for Bruker in a research report issued on Tuesday, February 12th. Jefferies Financial Group analyst B. Couillard now expects that the medical research company will earn $0.24 per share for the quarter, down from their previous forecast of $0.28. Jefferies Financial Group also issued estimates for Bruker’s Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.60 EPS, FY2019 earnings at $1.58 EPS and FY2020 earnings at $1.75 EPS.

• [By Logan Wallace]

  Shares of Bruker Co. (NASDAQ:BRKR) have received a consensus rating of “Hold” from the twelve brokerages that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $33.11.

• [By Max Byerly]

  Get a free copy of the Zacks research report on Bruker (BRKR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Stephan Byrd]

  Here are some of the media stories that may have effected Accern’s rankings:

  Get Bruker alerts: Bruker Announces Improved Solutions for Microbial Strain Typing, Hospital Hygiene and Infection Control, and Candida auris Testing at ASM 2018 (finance.yahoo.com) Financial Review: Bruker (BRKR) versus Pacific Biosciences of California (PACB) (americanbankingnews.com) Global Microbiology Testing/Clinical Microbiology Market 2018-2024: Market is Influenced by Biomerieux, Abbott, Roche, Bruker and Bio-rad Labs (bizjournals.com) Bruker Corporation appoints Gerald Herman as CFO (seekingalpha.com) Bruker Corporation Appoints Gerald Herman as Chief Financial Officer (finance.yahoo.com)

  A number of brokerages have issued reports on BRKR. Zacks Investment Research cut Bruker from a “buy” rating to a “hold” rating in a research report on Friday. BTIG Research set a $42.00 target price on Bruker and gave the stock a “buy” rating in a research report on Sunday, May 6th. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a research report on Wednesday, May 23rd. Bank of America decreased their target price on Bruker from $37.00 to $34.00 and set a “neutral” rating for the company in a research report on Friday, May 4th. Finally, Leerink Swann upped their target price on Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a research report on Friday, February 9th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $32.91.

• [By Stephan Byrd]

  Bruker Co. (NASDAQ:BRKR) has received an average recommendation of “Hold” from the eleven brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $34.38.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Bruker (BRKR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Low Price Stocks To Invest In Right Now: Briggs & Stratton Corporation(BGG)

Advisors' Opinion:

• [By ]

  For his "Executive Decision" segment, Cramer spoke with Todd Teske, chairman, president and CEO of Briggs & Stratton (BGG) , the small-engine maker that posted a penny-a-share earnings beat on Wednesday, but saw shares fall 11% on lighter-than-expected revenues and a cut in the company's full-year guidance.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on Briggs & Stratton (BGG)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Lisa Levin]

  Check out these big penny stock gainers and losers

  Losers Check-Cap Ltd. (NASDAQ: CHEK) fell 23.3 percent to $9.87 in pre-market trading after declining 13.45 percent on Wednesday. SunCoke Energy Partners, L.P. (NYSE: SXCP) fell 12.8 percent to $16.00 in pre-market trading after reporting Q1 results. Briggs & Stratton Corporation (NYSE: BGG) fell 11 percent to $17.55 in pre-market trading after the company posted mixed Q3 results and lowered its FY18 guidance. New Gold Inc. (NYSE: NGD) fell 8.4 percent to $2.30 in pre-market trading following downbeat Q1 results. Quality Care Properties, Inc. (NYSE: QCP) fell 8.2 percent to $20.85 in pre-market trading. Welltower announced plans to acquire QCP for $20.75 per share in cash. China Customer Relations Centers Inc. (NASDAQ: CCRC) shares fell 7.5 percent to $17.25 in pre-market trading after climbing 18.73 percent on Wednesday. Nokia Corporation (NYSE: NOK) shares fell 5.7 percent to $5.58 in pre-market trading after reporting Q1 results. eBay Inc. (NASDAQ: EBAY) fell 5.6 percent to $38.66 in pre-market trading following Q1 results. Southw
• [By Garrett Baldwin]

  By submitting your email address you will receive a free subscription to Profit Alerts and occasional special offers from Money Map Press and our affiliates. You can unsubscribe at anytime and we encourage you to read more about our privacy policy.

  Three Stocks to Watch Today: CSCO, M, BLK The earnings report calendar is headlined today by Cisco Systems Inc. (Nasdaq: CSCO). The tech giant will report fiscal fourth-quarter earnings after the bell. Wall Street expects that the firm will report earnings per share (EPS) of $0.69 on top of $12.77 billion in revenue. Shares of Macy's Inc. (NYSE: M) are on the move after the company reported earnings before the bell. The iconic retailer reported adjusted EPS of $0.70 on top of $5.57 billion in revenue. Wall Street had expected EPS of $0.49 on top of $5.61 billion in revenue. Shares of Macy's stock were off 5.3% in premarket hours. George Soros' firm Soros Fund Management increased its stake in shares of Blackrock Inc. (NYSE: BLK) by a whopping 60% in the second quarter, according to a U.S. Securities and Exchange Commission (SEC) filing. If you were using Money Morning's proprietary Stock VQScore, you'd have known that Blackrock was sitting in the "Buy Zone" before the SEC filing was made public. The global asset manager has a perfect 4.75 score, and it will look to blast off now that other investors start to follow Soros and other institutional investors that love this stock. To learn more about the Money Morning Stock VQScore, go here right now. Look for additional earnings reports from NetApp Inc. (Nasdaq: NTAP), MSG Networks Inc. (NYSE: MSGN), CACI International Inc. (NYSE: CACI), Briggs & Stratton Corp. (NYSE: BGG), SpartanNash Co. (Nasdaq: SPTN), and Luxoft Holding Inc. (NYSE: LXFT).

  Follow Money Morning on Facebook, Twitter, and LinkedIn.

• [By Jon C. Ogg]

  Generac Holdings Inc. (NYSE: GNRC) was up less than 1% at $59.20 late on Tuesday, but that is actually up by over 6% from last Friday’s close for the generator maker before the storm threat was so imminent. Briggs & Stratton Corp. (NYSE: BGG) is also in that field and its gain of just 0.3% to $20.45 late on Tuesday was actually up only about 1% from last Friday as the company is more diversified

Ideas for Profit: Here's what investors can expect after Arvind's demerger

Highlights:

- Anup Engineering and Arvind Fashions are anticipated to trade at premium valuations in due course
- For Arvind Ltd, re-rating will be predominantly driven by earnings traction
- The demerger will help unlock value once Arvind Fashion's valuation reflects the true potential of the business

--------------------------------------------------

Arvind Ltd, the textile major, first announced a plan to demerge the engineering and branded apparel divisions on November 8, 2017. After SEBI's approval, the demerger was finally effected on November 28, 2018.

While Anup Engineering got listed on the exchange on 1 March, 2019, Arvind Fashions got listed on March 8, 2019.

related news WPP appoints Microsoft UK CEO Cindy Rose to board Vidhi Specialty: Beneficiary of strong entry barriers in food colour industry

The core objective behind the exercise was to unlock value in each of the three verticals. Consequently, cash flows and profits from a particular segment would be utilised to fund growth strategies of the respective segment only.

A glance at the exhibit suggests that Arvind Fashions was incorrectly quoting at the exchanges ie. at a steep discount to its fair value on the first day of its listing (March 8, 2019). Therefore, Arvind Fashions is expected to continue its price rally till the fair value (in our view, this will be somewhere in the range of Rs 900 – 1,000) is discovered by the Street. It remains to be seen how markets value this coveted business from Arvind Ltd's stable.

Notwithstanding the glitch, here's a glance at how the 3 businesses are shaping up:-

Arvind Ltd (excluding Anup Engineering and Arvind Fashions)

Arvind Ltd's stock price post-demerger (ie. from November 28, 2018 onwards) hasn't had a good run. Besides market volatlity and weak Q3 numbers, here are a few concerns in the minds of investors that possibly hindered the stock's upmove:-

- High capex investments in relation to expansion of garmenting facilities
- Steep raw material (cotton) costs that may lead to margin pressure

- Overcapacity in denim fabrics, thus resulting in lower utilisation rates

Despite the above-mentioned challenges, the possibility of the stock re-rating in the long-term cannot be ignored if there is a sustainable revival in earnings. This, in turn, would depend on the following:-

- Introduction of value-added products in advanced materials (ie. technical textiles)
- Foray into manufacturing activewear and athleisure fabrics and garments

- Increased in-house captive consumption of fabrics for manufacturing apparel

Anup Engineering

Investors have been pretty bullish about the prospects of Anup Engineering because its products are pretty niche and high-margin in nature.

Besides being the third largest heavy fabrication player in India, the company caters to clients across specialised sectors such as petrochemicals, oil and gas, fertilisers and power.

Its financials are healthy too.

If Anup Engineering continues to deliver high RoCEs (return on capital employed) and generate positive free cash flows (as seen in the past) sustainably, it will command premium valuations.

Most stocks in the capital goods space have been plagued with issues such as highly leveraged balance sheets, a weak demand environment and input cost hikes, among others. So, any outperformance by Anup Engineering compared to its peers will, almost certainly, result in a big price upside.

Arvind Fashions

Arvind Fashions has shown consistent improvement in its margins since the past few quarters. This, coupled with a strong portfolio of brands and promising potential of Indian retail, caught the attention of investors. Going forward, here are the factors that will influence the company's performance:-

- Store additions in brands and speciality retail
- Accelerated foray into leisurewear
- Operating leverage from power brands

- Economies of scale and strong private label brands in 'Unlimited', the affordable fashion format

Is there any value proposition in store?

For investors that held shares of Arvind Ltd pre-demerger and continue to hold them now as well (ie. after the 3 businesses are separately listed), Arvind Fashions will continue with its price upmove in the near-term till it reaches its fair value. In times to come, it should contribute the most in terms of shareholders' value creation.

While Anup Engineering's historical positives are already discounted in the stock's price, Arvind Ltd will have to prove its mettle convincingly.

Follow @krishnakarwa152

For more research articles, visit our Moneycontrol Research page

(Disclaimer: Moneycontrol Research analysts do not hold positions in the companies discussed here) First Published on Mar 12, 2019 01:38 pm

Microchip Technology Inc. (MCHP) Receives Consensus Recommendation of “Buy” from Analyst

Microchip Technology Inc. (NASDAQ:MCHP) has earned an average recommendation of “Buy” from the twenty-one brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $102.75.

A number of equities analysts have recently issued reports on the stock. BidaskClub raised shares of Microchip Technology from a “sell” rating to a “hold” rating in a research report on Friday, November 16th. Cowen assumed coverage on shares of Microchip Technology in a research report on Friday, February 22nd. They set a “market perform” rating and a $90.00 price objective on the stock. BMO Capital Markets assumed coverage on shares of Microchip Technology in a research report on Monday, November 12th. They set an “outperform” rating and a $92.00 price objective on the stock. Citigroup reissued a “buy” rating and set a $105.00 price objective on shares of Microchip Technology in a research report on Thursday, February 7th. Finally, Zacks Investment Research raised shares of Microchip Technology from a “sell” rating to a “hold” rating in a research report on Monday, December 10th.

Get Microchip Technology alerts:

Microchip Technology stock traded up $0.60 during trading hours on Friday, reaching $85.05. 1,802,323 shares of the company’s stock were exchanged, compared to its average volume of 3,054,305. The company has a current ratio of 2.92, a quick ratio of 1.83 and a debt-to-equity ratio of 2.04. Microchip Technology has a twelve month low of $60.70 and a twelve month high of $104.20. The company has a market cap of $20.15 billion, a P/E ratio of 16.39, a PEG ratio of 1.13 and a beta of 1.21.

Microchip Technology (NASDAQ:MCHP) last released its quarterly earnings data on Tuesday, February 5th. The semiconductor company reported $1.66 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.45 by $0.21. The company had revenue of $1.42 billion for the quarter, compared to analysts’ expectations of $1.40 billion. Microchip Technology had a net margin of 6.53% and a return on equity of 32.30%. The business’s revenue was up 42.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.36 EPS. Equities research analysts forecast that Microchip Technology will post 5.89 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 7th. Investors of record on Thursday, February 21st were given a $0.365 dividend. This is a boost from Microchip Technology’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend was Wednesday, February 20th. This represents a $1.46 annualized dividend and a yield of 1.72%. Microchip Technology’s dividend payout ratio (DPR) is presently 28.13%.

In related news, Director Matthew W. Chapman sold 4,660 shares of the firm’s stock in a transaction dated Friday, February 15th. The shares were sold at an average price of $91.04, for a total value of $424,246.40. Following the transaction, the director now owns 19,080 shares of the company’s stock, valued at approximately $1,737,043.20. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Mitchell R. Little sold 3,585 shares of the firm’s stock in a transaction dated Wednesday, February 13th. The shares were sold at an average price of $91.17, for a total transaction of $326,844.45. Following the completion of the transaction, the vice president now directly owns 7,693 shares in the company, valued at approximately $701,370.81. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,601 shares of company stock worth $961,340. 2.13% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in MCHP. Clarfeld Financial Advisors LLC purchased a new stake in Microchip Technology in the 4th quarter valued at about $26,000. Oregon Public Employees Retirement Fund increased its stake in Microchip Technology by 7,043.2% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,841,512 shares of the semiconductor company’s stock valued at $26,000 after buying an additional 1,815,732 shares during the last quarter. Morgan Dempsey Capital Management LLC purchased a new stake in Microchip Technology in the 4th quarter valued at about $28,000. Lindbrook Capital LLC purchased a new stake in Microchip Technology in the 4th quarter valued at about $32,000. Finally, Enlightenment Research LLC purchased a new stake in Microchip Technology in the 4th quarter valued at about $43,000.

Microchip Technology Company Profile

Microchip Technology Incorporated develops, manufactures, and sells semiconductor products for various embedded control applications. The company offers general purpose and specialized 8-bit, 16-bit, and 32-bit microcontrollers; 32-bit microprocessors; and microcontrollers for automotive networking, computing, lighting, power supplies, motor control, human machine interface, security, wired connectivity, and wireless connectivity.

See Also: Inflation

NantHealth (NH) Sees Large Volume Increase

NantHealth Inc (NASDAQ:NH) shares saw strong trading volume on Friday . 6,118,098 shares traded hands during trading, an increase of 1,566% from the previous session’s volume of 367,215 shares.The stock last traded at $1.19 and had previously closed at $1.08.

Separately, Zacks Investment Research upgraded shares of NantHealth from a “strong sell” rating to a “hold” rating in a report on Wednesday, January 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $4.08.

Get NantHealth alerts:

The company has a market cap of $147.07 million, a P/E ratio of -1.06 and a beta of 0.86. The company has a current ratio of 1.24, a quick ratio of 1.23 and a debt-to-equity ratio of 3.89.

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in NantHealth in the fourth quarter valued at $29,000. Paloma Partners Management Co acquired a new stake in NantHealth in the fourth quarter valued at $31,000. Vanguard Group Inc lifted its stake in NantHealth by 2.3% in the third quarter. Vanguard Group Inc now owns 646,248 shares of the company’s stock valued at $1,015,000 after acquiring an additional 14,515 shares during the last quarter. Finally, BlackRock Inc. lifted its stake in NantHealth by 1.5% in the third quarter. BlackRock Inc. now owns 2,373,118 shares of the company’s stock valued at $3,725,000 after acquiring an additional 35,869 shares during the last quarter. Hedge funds and other institutional investors own 4.42% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “NantHealth (NH) Sees Large Volume Increase” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/4207535/nanthealth-nh-sees-large-volume-increase.html.

NantHealth Company Profile (NASDAQ:NH)

NantHealth, Inc, together with its subsidiaries, operates as an evidence-based personalized healthcare company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care.

See Also: Fundamental Analysis and Choosing Stocks

Citigroup Inc. Raises Position in Amdocs Limited (DOX)

Citigroup Inc. boosted its position in shares of Amdocs Limited (NASDAQ:DOX) by 0.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 86,236 shares of the technology company’s stock after buying an additional 695 shares during the quarter. Citigroup Inc.’s holdings in Amdocs were worth $5,052,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of DOX. Riverview Trust Co acquired a new position in Amdocs during the 4th quarter worth $27,000. Cutler Group LP acquired a new position in Amdocs during the 4th quarter worth $55,000. Oppenheimer Asset Management Inc. acquired a new position in Amdocs during the 4th quarter worth $58,000. Honkamp Krueger Financial Services Inc. acquired a new position in Amdocs during the 3rd quarter worth $124,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Amdocs during the 4th quarter worth $222,000. Hedge funds and other institutional investors own 91.10% of the company’s stock.

Get Amdocs alerts:

DOX stock opened at $54.21 on Friday. The firm has a market capitalization of $7.93 billion, a PE ratio of 15.53, a P/E/G ratio of 1.70 and a beta of 0.53. Amdocs Limited has a twelve month low of $52.60 and a twelve month high of $71.72.

Amdocs (NASDAQ:DOX) last posted its quarterly earnings results on Tuesday, February 5th. The technology company reported $0.98 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.99 by ($0.01). The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Amdocs had a net margin of 8.46% and a return on equity of 14.75%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same period last year, the company earned $1.06 EPS. Sell-side analysts forecast that Amdocs Limited will post 3.92 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 19th. Stockholders of record on Friday, March 29th will be paid a $0.285 dividend. The ex-dividend date is Thursday, March 28th. This represents a $1.14 dividend on an annualized basis and a dividend yield of 2.10%. This is an increase from Amdocs’s previous quarterly dividend of $0.25. Amdocs’s dividend payout ratio is 26.74%.

Several research analysts have issued reports on DOX shares. TheStreet downgraded Amdocs from a “b” rating to a “c+” rating in a report on Friday, November 9th. Zacks Investment Research downgraded Amdocs from a “hold” rating to a “sell” rating in a report on Monday, November 19th. BidaskClub downgraded Amdocs from a “buy” rating to a “hold” rating in a report on Wednesday, November 28th. JPMorgan Chase & Co. set a $70.00 price objective on Amdocs and gave the stock a “hold” rating in a report on Tuesday, December 11th. Finally, ValuEngine downgraded Amdocs from a “hold” rating to a “sell” rating in a report on Friday, February 15th. Two analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $71.03.

TRADEMARK VIOLATION WARNING: “Citigroup Inc. Raises Position in Amdocs Limited (DOX)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4205662/citigroup-inc-raises-position-in-amdocs-limited-dox.html.

Amdocs Profile

Amdocs Limited, through its subsidiaries, provides software and services to the communications, pay TV, entertainment, and media industry service providers worldwide. The company offers amdocsONE a line of services designed for various stages of a service provider's lifecycle, including planning, delivery, implementation, and ongoing support, as well as consumer experience and monetization, media and digital, enterprise and connected society, service-driven network, and services and agile operation solutions.

Featured Story: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding DOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amdocs Limited (NASDAQ:DOX).